Jazz Reports Results of Nabiximols Oromucosal Spray in P-III (RELEASE MSS1) Trial for the Treatment of Multiple Sclerosis Spasticity
- The P-III (RELEASE MSS1) trial evaluated nabiximols oromucosal spray in a ratio (1:1) in 68 adult patients with MS spasticity for 3wk.
- The trial failed to meet the 1EPs of change in LLMT-6 b/w baseline & Day 21 as measured by MAS & 2EPs include a change in LLMT-4 as defined by the MAS. The safety profile was consistent with prior reported AEs with no new safety signals to nabiximols oromucosal spray
- Nabiximols oromucosal spray also known as Sativex (Ex-US and 1st approved in the UK in 2010) has been approved in 29 countries for mod. to sev. spasticity due to MS who have not responded adequately to other anti-spasticity medication based on prior completed clinical trials
Ref: PRNewswire | Image: Jazz
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].